文献速递神经肌肉病

利妥昔单抗治疗青少年重症肌无力:法国经验

Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
PubMed 文献 · Neurology · 2022-03-21

本研究为回顾性多中心研究,纳入法国8个儿科神经肌肉参考中心2009年1月1日至2020年4月30日的74例青少年重症肌无力患儿,其中27例接受利妥昔单抗治疗。结果显示,利妥昔单抗治疗组结局优于传统免疫抑制剂组(p=0.006);一线使用利妥昔单抗较二线或三线使用更易停用免疫抑制剂(75% vs 25%,p=0.04)并减少激素用量(42% vs 92%,p=0.03),且耐受良好,未观察到不良反应。

要点

  • 利妥昔单抗治疗组结局优于传统免疫抑制剂组(p=0.006)。
  • 一线使用利妥昔单抗者停用免疫抑制剂比例75%,二线或三线使用者为25%(p=0.04)。
  • 一线使用利妥昔单抗者激素节省比例42%,二线或三线使用者为92%(p=0.03)。

核心结论

  • 利妥昔单抗在青少年重症肌无力中耐受性良好且有效,早期使用可能改善结局并有助于抗体阳性全身型青少年重症肌无力患者节省激素。

研究设计与样本

  • 回顾性多中心研究,纳入2009年1月1日至2020年4月30日法国8个儿科神经肌肉参考中心(FILNEMUS网络)的74例重症肌无力患儿,其中眼肌型18例、全身型56例。

主要发现

  • 37例需要免疫抑制治疗的患者中,27例接受利妥昔单抗治疗。
  • 利妥昔单抗治疗组结局优于传统免疫抑制剂治疗组(p=0.006)。
  • 一线使用利妥昔单抗者停用免疫抑制剂的比例为75%,二线或三线使用者为25%(p=0.04)。
  • 一线使用利妥昔单抗者激素节省比例为42%,二线或三线使用者为92%(p=0.03)。
  • 利妥昔单抗耐受良好,未观察到不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Corticosteroids are the first-line immunosuppressants in the management of juvenile myasthenia gravis despite their adverse effects. The place of new immunosuppressive therapies is not clearly defined by the last international consensus held in March 2019 due to the lack of clinical trials. The aim of this study is to describe the use of rituximab and its efficacy and safety in 8 main pediatric centers of the French neuromuscular reference network to propose a new place in the therapeutic strategy of juvenile myasthenia gravis. METHODS: We conducted a retrospective multicenter study from January 1, 2009, to April 30, 2020, including a large cohort of children with myasthenia gravis in 8 main French pediatric reference centers of the FILNEMUS network. The type of myasthenia, different lines of immunosuppressive treatment, and clinical course of the patients were collected. To evaluate the efficacy of rituximab, we studied the clinical course of patients on immunosuppressive therapy. Outcome was defined as the clinical and therapeutic status of patients at the last visit: stable without immunosuppressants, stable with immunosuppressants, or unstable. RESULTS: We included 74 patients: 18 children with ocular form and 56 children with generalized form. Of the 37 patients who required immunosuppressive therapy, 27 were treated with rituximab. Patients treated with rituximab had a better outcome than patients treated with conventional immunosuppressants (p = 0.006). The use of rituximab as a first-line immunosuppressant showed a better efficacy with a discontinuation of immunosuppressants in 75% of patients (vs 25%, p = 0.04) and results in cortisone sparing (42% vs 92%, p = 0.03) compared with rituximab treatment as a second- or third-line immunosuppression. Rituximab was well tolerated; no adverse effect was observed. DISCUSSION: The use of rituximab has increased in France over the last 10 years as a first-line immunosuppressant. This study suggests good tolerability and efficacy of rituximab in juvenile myasthenia gravis. Early use appears to improve outcomes and facilitate cortisone sparing in antibody-positive generalized juvenile myasthenia. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for children with MG, rituximab is effective and well tolerated.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Molimard A, Gitiaux C, Barnerias C, et al. Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience. Neurology. 2022. PMID: 35314497. doi:10.1212/WNL.0000000000200288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。